Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 9 of the 30 sources its claims cite were checked for support.
Abstract
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3 “parent” studies could continue esketamine treatment, combined with an oral antidepressant, by enrolling in phase 3, open-label, long-term extension study, SUSTAIN-3. Based on their status at parent-study end, eligible participants entered a 4-week induction phase followed by an optimization/maintenance phase, or directly entered the optimization/maintenance phase of SUSTAIN-3. Intranasal esketamine dosing was flexible, twice-weekly during induction and individualized to depression severity during optimization/maintenance. At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance. Mean (median) cumulative duration of maintenance esketamine treatment was 31.5 (37.7) months (totaling 2769 cumulative patient-years). Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis. Mean Montgomery–Åsberg Depression Rating Scale (MADRS) total score decreased during induction, and this reduction persisted during optimization/maintenance (mean [SD] change from the baseline to the endpoint of each phase: induction −12.8 [9.73]; optimization/maintenance +1.1 [9.93]), with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively. Improvement in depression ratings generally persisted among participants who remained in maintenance treatment, and no new safety signal was identified during long-term treatment (up to 4.5 years) using intermittent-dosed esketamine in conjunction with daily antidepressant.
Overview
CoChat Summary
TL;DR
In this interim analysis of the phase 3 SUSTAIN-3 long-term extension, esketamine nasal spray plus an oral antidepressant was associated with sustained improvement in depressive symptoms and no new safety signal in adults with treatment-resistant depression followed for up to 4.5 years. Common adverse events were mostly mild/moderate and transient, with headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis among the most frequent.
Key findings
- Among 1148 enrolled participants, mean (median) cumulative maintenance esketamine exposure was 31.5 (37.7) months, totaling 2769 cumulative patient-years; 81.0% were exposed ≥12 months and 48.4% ≥36 months.
- MADRS total score decreased during induction (mean [SD] change −12.8 [9.73]) and remained stable during optimization/maintenance (+1.1 [9.93]); remission (MADRS ≤12) was 35.6% at induction endpoint and 46.1% at optimization/maintenance endpoint.
- Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis; 96.8% of adverse events were mild or moderate, and 5.8% discontinued study drug due to adverse events.
- No new safety signal was identified; no psychosis was reported, no treatment-related interstitial/ulcerative cystitis was identified, and serious adverse events were reported in 14.9% of participants, with 5 deaths (0.4%) none considered related to esketamine.
Methods
- Phase 3, open-label, multicenter (n = 59), long-term extension study of adults with treatment-resistant depression who had participated in ≥1 of 6 phase 3 parent studies; participants entered a 4-week induction phase or directly entered optimization/maintenance based on parent-study status.
- Esketamine nasal spray was self-administered under medical supervision at flexible doses (28 mg for age ≥65 years, 56 mg, or 84 mg) twice weekly during induction and individualized to depression severity during optimization/maintenance, combined with an investigator-prescribed oral antidepressant.
- Safety and efficacy were summarized descriptively at an interim data cutoff of 01 December 2020; assessments included treatment-emergent adverse events, MADRS, PHQ-9, CGI-S, SDS, C-SSRS, cognitive testing, and vital signs.
Limitations
- The paper states that generalizability is limited by potential bias related to which participants chose to continue from parent studies, exclusion of participants with significant psychiatric or medical comorbidities or substance dependence, and limited racial heterogeneity (86.8% white); sample size decreased at later time points, and the data are interim and continue to be updated.
- The paper notes that without a placebo group it is difficult to determine to what extent slowing of reaction time in participants ≥65 years reflects study drug, and that ketamine abuse could not have been detected if participants obtained illicit drug because the urine drug screen did not assay for the r-enantiomer of ketamine or its metabolites.
- Evident from the text: the study is open-label, so efficacy findings may be influenced by lack of blinding and no randomized comparator during long-term treatment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 SUSTAIN-3 Participant Disposition. aOne each: scheduling conflicts; multiple reasons (mainly, feeling better, wanted to start working again, adverse events, and time requirements of study); withdrew consent; participant’s choice despite investigator’s advice to continue; relocation; and death on study day 26 due to completed suicide, 4 days after the last dose of esketamine. bOther reasons (each ≤1%, e.g., investigator/sponsor decision, employment/school, personal reasons, death [4 participants, as described in Supplementary Material]). Note: Participants were eligible to enroll into the Induction Phase or the Optimization/Maintenance Phase based on their status at the end of the parent study (refer to Table S2). Participants received open-label esketamine nasal spray (28 mg [only an option for participants ≥65 years], 56 mg, or 84 mg) twice per week during the Induction Phase, and weekly, every other week, or every 4 weeks, based on clinical global impression - severity (CGI-S) and tolerability, during the Optimization/Maintenance Phase.](https://figures.cochat.ai/paper-figures/eb35d8ce6f4744c193835e1292649b5f/long-term-safety-and-maintenance-of-response-with-esketamine-nasal-spray-in-figure-1.jpg)


Verification
Claims the paper makes
4 Valid · 0 Not valid · 12 Not checked · 106 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients with TRD have pronounced decreases in daily functioning and health-related quality of life, compared to non-TRD MDD patients [6]”
§ Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study > Introduction
What the sources say
- Supportedcites [6] DiBernardo A, Lin X, Zhang Q, Xiang J, Lu L, Jamieson C, et al. Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study. BMC Psychiatry. 2018;18:352. source
The Discussion (p. opening paragraph) states that STAR*D patients meeting TRD criteria had worse HRQOL, work productivity and greater functional impairments than non-TRD patients, and the Results section 'Work and social functional impairment' reports significantly higher WSAS (23.4 vs 11.3) and all WPAI scales, including activity impairment (54.5% vs 30.5%, p < .0001) — i.e. markedly greater impairment in daily activities. Table 3 and the Abstract Results give the corresponding HRQOL decrements (SF-12 mental component 30.0 vs 45.7; Q-LES-Q general activities index 43.6 vs 63.7, both p < .0001). Both halves of the claim — daily functioning and health-related quality of life, versus non-TRD MDD — are stated in our copy, and the magnitudes/'pronounced' characterisation matches the large, highly significant differences reported. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The approvals of esketamine nasal spray were based on efficacy and safety findings from phase 2/3 studies of TRD treatment for 4 weeks to 1 year [9–14].”
§ Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study > Introduction
What the sources say
- Partly supportedcites [9] Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139–48. sourceExperimental — accuracy not yet measured
Our copy confirms only the identification part of the claim: Daly et al. (2018) is a phase 2 trial reporting efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in TRD (Design, p. 1: 'This phase 2, 2-panel, double-blind, doubly randomized, delayed-start, placebo-controlled study'; Abstract/Results report MADRS superiority and the Safety section reports adverse events). It does not support the rest: nothing in our copy states or implies that regulatory approvals of esketamine nasal spray were based on these findings — on the contrary the Conclusions say 'Results support further investigation of intranasal efficacy of esketamine for the treatment of TRD in larger trials. A phase 3 study evaluating the necessary frequency of dosing and duration of effect is under way.' The claimed treatment duration of '4 weeks to 1 year' also does not match this study, whose double-blind treatment lasted days 1-15 (two 1-week periods) with an optional open-label phase to day 74 plus 8-week follow-up (Design; Participants/eFigure timeline). (LLM, conf=0.75)
- Partly supportedcites [10] Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:893–903. sourceExperimental — accuracy not yet measured
Our copy confirms the trial-level part of the attribution: SUSTAIN-1 is a phase 3, multicenter, double-blind randomized-withdrawal study in adults with prospectively confirmed TRD that reports both efficacy (time to relapse) and safety findings, and its Discussion states that results were 'consistent with previous findings from completed short-term (4-week) phase 2 and 3 studies' while calling itself a 'long-term study' of weekly/biweekly esketamine (Abstract; Study Population; Discussion). What our copy does not support is the regulatory half of the sentence: no passage says esketamine nasal spray was approved, or that any approval rested on these phase 2/3 studies (the only 'approvals' mentioned are IRB/ethics-committee approval of the protocol). The upper bound 'to 1 year' is also not stated as such — after 16 weeks of induction/optimization, median esketamine exposure in the variable-duration maintenance phase was 17.7 weeks (stable remission) and 19.4 weeks (stable response), i.e. roughly 8-9 months of treatment (Results, Conclusions figure legend). (LLM, conf=0.72)
- Supportedcites [11] Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22:616–30. source
The Introduction records that esketamine 'has recently been approved in the United States as a nasal spray formulation for TRD treatment' and immediately situates that approval within the phase 2 (Singh 2016; Daly 2018) and phase 3 (Popova 2019; Daly 2019) TRD efficacy/safety programme, so this paper is one of the phase 2/3 TRD studies the range citation [9–14] points to. Its Abstract Methods and Conclusions confirm it is a Phase 3 trial in adults with TRD in which nasal spray esketamine (56 or 84 mg) or placebo was given twice weekly with a newly initiated oral antidepressant 'daily for 4 weeks' (primary endpoint day 28) and that it 'provides supportive evidence for the safety and efficacy of esketamine nasal spray'. The upper end of the stated duration range is not this trial's: the Discussion limitations state it 'assessed only the short-term efficacy and safety' and that maintenance of effect and long-term safety 'were evaluated in other studies (Daly et al., 2019; Wajs et al., 2018)', i.e. other members of the cited set — consistent with a range citation rather than a misattribution. (LLM, conf=0.80)
- Not checked yetcites [12] Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28:121–41. source
- Partly supportedcites [13] Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428–38. sourceExperimental — accuracy not yet measured
The Study Design and Results sections identify this as a phase 3 study of four weeks of esketamine treatment for treatment-resistant depression and report efficacy and safety findings. The paper mentions FDA approval, but does not say that approval was based on these findings; it explicitly says this trial does not inform long-term safety, so it cannot support the one-year duration attributed to the cited studies collectively. (LLM, conf=0.87)
- Partly supportedcites [14] Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81:19m12891. sourceExperimental — accuracy not yet measured
Our copy confirms the study-level part of the claim: the Abstract describes SUSTAIN-2 as a 'phase 3, open-label, multicenter, long-term (up to 1 year) study' in patients with TRD, with a 4-week induction phase followed by a 48-week optimization/maintenance phase, and the Discussion reports both safety (TEAE profile) and efficacy outcomes ('Reductions in depressive symptoms were observed during the first 4 weeks of treatment (IND phase) and appeared to be sustained through the 1-year exposure period'). So this paper is genuinely one of the phase 3 TRD trials of 4 weeks to 1 year reporting efficacy and safety. However, no passage in our copy addresses the regulatory assertion — that the approvals of esketamine nasal spray were based on these findings (searched: approval, FDA, indication, regulatory authorities); the paper instead notes long-term safety data 'have been lacking prior to the current study,' and it is phase 3 only, not phase 2. The approval-basis and phase 2 components rest on the other citations in the range [9-14], not on this source. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The incidence of clinically-relevant sedation (MOAA/S score ≤ 3) in SUSTAIN-3 (6.1% in the induction phase and 6.9% in the optimization/maintenance phase) is similar to that observed in the prior long-term SUSTAIN-2 study (8.4% and 7.0% in the respective phases) [14].”
§ Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study > Discussion
What the sources say
- Supportedcites [14] Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81:19m12891. source
The Sedation subsection of our copy states verbatim that clinically-relevant sedation, defined by MOAA/S score ≤ 3, occurred in 8.4% of patients in the IND phase and 7.0% in the OP/MAINT phase of SUSTAIN-2, matching both figures and the phase attribution in the citing sentence. The SUSTAIN-3 comparison figures belong to the citing paper's own study and are not attributed to this source. Our copy also defines the same MOAA/S ≤ 3 threshold, so the operational definition is consistent. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of esketamine, with continuous intermittent dosing for up to 4.5 years in SUSTAIN-3 (2,769 cumulative patient-years), is consistent with its established safety profile in participants with TRD treated for up to 1 year [7, 8, 14].”
§ Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study > Discussion
What the sources say
- Not checked yetcites [7] SpravatoTM (esketamine) nasal spray Prescribing Information. © 2020 Janssen Pharmaceutical Companies.
- Not checked yetcites [8] Spravato (esketamine) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf. Accessed 18 September 2022.
- Partly supportedcites [14] Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81:19m12891. sourceExperimental — accuracy not yet measured
Our copy of Wajs et al. 2020 (SUSTAIN-2) supports only the second half of the sentence: the Discussion and Clinical Points state that long-term (up to 1 year) esketamine nasal spray plus a new OAD in 802 patients with TRD showed acceptable tolerability and an adverse-event profile consistent with the known short-term safety profile. The SUSTAIN-3 elements the sentence attributes to the citation — continuous intermittent dosing for up to 4.5 years and 2,769 cumulative patient-years — are absent from our copy; the paper only notes (Patients and Disposition) that 463 patients continued esketamine in a separate open-label extension safety study (NCT02782104), without reporting that extension's duration or exposure. (LLM, conf=0.78)
plainn = 2,769- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis.”
§ Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study > Abstract
plainn = 1,148- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
70 more claims
Create a free account to see all 122 claims and to verify the 21 references still open.
- It may state two separate claims as one. 40
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results were positive, showing that the same improvement of depressive symptoms at the first 4 weeks of exposure to the drug were sustained during the 2-year mark at the end of the study, with a very small percentage of patients discontinuing the study because of worsening depression (0.6%) or suicide ideation (0.2%).”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“a few participants (0.8%) received treatment with concomitant medication(s) for dissociation, which primarily (4 of 8 participants) consisted of single doses of a benzodiazepine anxiolytic”
§ Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study > Results > Safety
Reported 0.8 · recomputed 0.696864
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“Even when patients with TRD respond, the relapse rate is high (~70%) within 6 months [5].”
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“While up to 20% of patients with MDD attempt suicide over their lifetime [27, 28], with an estimated lifetime risk of 3.”
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987 · cited 1×
“Participants rated the impact of the study treatments on sociooccupational disability using the Sheehan Disability Scale [20] (SDS) and on depressive symptoms using the Patient Health Questionnaire 9-item [21] (PHQ-9).”
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Self-citation
Cited by
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial
Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Macaluso, M., Mattingly, G. W., Shelton, R. C., Zajecka, J. M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1317 · Cited by 54
Self-citationPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“A very recent open-label, long-term study accessed the safety and efficacy of esketamine use in patients with TRD [114].”
BackgroundCastro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P., Zaki, N., Borentain, S., Fu, D. J., Turkoz, I., Sun, L., Brown, B., et al. (2023) · CNS Drugs · doi:10.1007/s40263-023-01026-3 · Cited by 25
Self-citationLan, X., Wang, C., Zhang, F., Liu, H., Li, W., Ye, Y., Hu, Z., Mai, S., Ning, Y., & Zhou, Y. (2023) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-023-00647-2 · Cited by 22
“An open-label, multicenter, long-term study evaluated the safety of esketamine nasal spray in 779 adults with TRD, suggesting that cognitive performances, including measures of simple and choice reaction time, visual and verbal learning and memory, working memory, and executive function, either improved or remained st…”
Background
Metadata
- Authors
- Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J.
- Affiliations
- Janssen Research & Development (United States) (US)
- Janssen (United States) (US)
- Yale University (US)
- Janssen (Belgium) (BE)
- Corresponding author
- Zaki, Naim
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2023-05-12
- Volume
- 48
- Issue
- 8
- Pages
- 1225-1233
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC10267177
- OpenAlex
- W4376274076
- Cited by
- 137
- References
- 31
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 41 · 2023: 15
- FWCI
- 21.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- FOCUS The Journal of Lifelong Learning in Psychiatry (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- Janssen Research & Development LLC, Titusville, NJ USA
- Janssen Research & Development, LLC, Titusville, NJ, US
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, treatment-resistant depression, long-term maintenance therapy, long-term tolerability, relapse prevention, intermittent dosing, treatment-emergent adverse events, depression remission
- MeSH terms
- Adult, Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Ketamine, Quality of Life, Treatment Outcome, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. https://app.cochat.ai/papers/10.1038/s41386-023-01577-5
- The paper
- Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01577-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.